This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

LifeSci Advisors Announces Investment Opinion On Transition Therapeutics, Inc.

LifeSci Advisors, LLC, a leading provider of investment research and investor relations services in the life sciences sector, today announced that it has initiated coverage of Transition Therapeutics, Inc. ("Transition") (TSX: TTH) (NASDAQ: TTHI), a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include:

  • ELND005: small molecule drug to enter Phase 3 for the treatment of Alzheimer's disease
  • TT401/TT402: long-acting GLP-1 dual agonists for type 2 diabetes that provide glycemic control, weight management, improved lipid profile and better GI tolerability
  • TT301/TT302: novel orally bioavailable aminopyridizines for rheumatoid arthritis, that inhibit multiple pro-inflammatory cytokines and chemokines

“Transition’s strong record of executing against their business model is quite impressive,” said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. “They have a strong cash position, no debt, and their lead drug, ELND005, is poised to enter Phase 3 for Alzheimer’s disease in partnership with Elan, who are responsible for all Phase 3 costs, leaving only upside potential for Transition. With ELND005’s disease-modifying mechanism and oral dosing advantage, it is positioned to compete successfully in the burgeoning Alzheimer’s disease space, a market with potential to exceed $10 Billion in annual worldwide sales. Transition’s earlier stage pipeline includes diabetes compounds TT401/402 which have a highly compelling profile and TT301/TT302, which are positioned for success in rheumatoid arthritis as oral successors to the current biologic therapies.”

In a 53-page Initiation Report by LifeSci Advisors, the preclinical and clinical achievements of ELND005 to date are presented, as is a detailed analysis favoring use of the drug in early stage Alzheimer’s patients. The safety and pharmacokinetics of ELND005 has been evaluated in a total of nine Phase 1 studies in 161 healthy volunteers, including healthy elderly subjects. A recently completed Phase 2 study called AD201 was a randomized, double-blind, placebo-controlled, dose-ranging study for ELND005 in patients with mild to moderate Alzheimer’s disease. For AD201, mild to moderate patients, aged 50-85 years were randomized, and an open label extension of the study called AD251 is ongoing. The report also examines the rapidly changing landscape for drug development in the growing Alzheimer’s disease space, including the ongoing paradigm shift within the field regarding increasing use of biomarkers and the evolving perspective on selection of inclusion criteria and endpoints for clinical studies. Also emphasized is the importance of providing disease modifying therapy to patients at earlier stages of the disease, where the potential for patient benefit is greatest.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,985.61 +78.99 0.47%
S&P 500 1,972.83 +9.12 0.46%
NASDAQ 4,419.0340 +27.5710 0.63%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs